471 related articles for article (PubMed ID: 18227703)
1. Postoperative morbidity of lymph node excision for cutaneous melanoma-sentinel lymphonodectomy versus complete regional lymph node dissection.
Kretschmer L; Thoms KM; Peeters S; Haenssle H; Bertsch HP; Emmert S
Melanoma Res; 2008 Feb; 18(1):16-21. PubMed ID: 18227703
[TBL] [Abstract][Full Text] [Related]
2. [Surgical technique and postoperative morbidity following radical inguinal/iliacal lymph node dissection--a prospective study in 67 patients with malignant melanoma metastatic to the groin].
Mall JW; Reetz C; Koplin G; Schäfer-Hesterberg G; Voit C; Neuss H
Zentralbl Chir; 2009 Sep; 134(5):437-42. PubMed ID: 19757344
[TBL] [Abstract][Full Text] [Related]
3. Morbidity after inguinal sentinel lymph node biopsy and completion lymph node dissection in patients with cutaneous melanoma.
de Vries M; Vonkeman WG; van Ginkel RJ; Hoekstra HJ
Eur J Surg Oncol; 2006 Sep; 32(7):785-9. PubMed ID: 16806794
[TBL] [Abstract][Full Text] [Related]
4. Morbidity and recurrence after completion lymph node dissection following sentinel lymph node biopsy in cutaneous malignant melanoma.
Guggenheim MM; Hug U; Jung FJ; Rousson V; Aust MC; Calcagni M; Künzi W; Giovanoli P
Ann Surg; 2008 Apr; 247(4):687-93. PubMed ID: 18362633
[TBL] [Abstract][Full Text] [Related]
5. Inguinal node dissection for melanoma in the era of sentinel lymph node biopsy.
Sabel MS; Griffith KA; Arora A; Shargorodsky J; Blazer DG; Rees R; Wong SL; Cimmino VM; Chang AE
Surgery; 2007 Jun; 141(6):728-35. PubMed ID: 17560249
[TBL] [Abstract][Full Text] [Related]
6. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
Nowecki ZI; Rutkowski P; Michej W
Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535
[TBL] [Abstract][Full Text] [Related]
7. Complete lymph node dissection for regional nodal metastasis.
Dzwierzynski WW
Clin Plast Surg; 2010 Jan; 37(1):113-25. PubMed ID: 19914463
[TBL] [Abstract][Full Text] [Related]
8. Lymph node dissection in patients with malignant melanoma is associated with high risk of morbidity.
Ul-Mulk J; Hölmich LR
Dan Med J; 2012 Jun; 59(6):A4441. PubMed ID: 22677239
[TBL] [Abstract][Full Text] [Related]
9. Is there increased risk of local and in-transit recurrence following sentinel lymph node biopsy?
Cerovac S; Mashhadi SA; Williams AM; Allan RA; Stanley PR; Powell BW
J Plast Reconstr Aesthet Surg; 2006; 59(5):487-93. PubMed ID: 16631558
[TBL] [Abstract][Full Text] [Related]
10. Multivariable analysis comparing outcome after sentinel node biopsy or therapeutic lymph node dissection in patients with melanoma.
van Akkooi AC; Bouwhuis MG; de Wilt JH; Kliffen M; Schmitz PI; Eggermont AM
Br J Surg; 2007 Oct; 94(10):1293-9. PubMed ID: 17702089
[TBL] [Abstract][Full Text] [Related]
11. Sentinel lymph node micrometastasis may predict non-sentinel involvement in cutaneous melanoma patients.
Glumac N; Hocevar M; Zadnik V; Snoj M
J Surg Oncol; 2008 Jul; 98(1):46-8. PubMed ID: 18452214
[TBL] [Abstract][Full Text] [Related]
12. Prognosis and surgical management of patients with palpable inguinal lymph node metastases from melanoma.
Hughes TM; A'Hern RP; Thomas JM
Br J Surg; 2000 Jul; 87(7):892-901. PubMed ID: 10931025
[TBL] [Abstract][Full Text] [Related]
13. [Complication of radical lymph node dissection following sentinel lymph node biopsy in patients with melanoma].
Litrowski N; Duval Modeste AB; Coquerel D; Courville P; Milliez PY; Joly P
Ann Dermatol Venereol; 2013; 140(6-7):425-30. PubMed ID: 23773739
[TBL] [Abstract][Full Text] [Related]
14. Morbidity after axillary sentinel lymph node biopsy in patients with cutaneous melanoma.
de Vries M; Vonkeman WG; van Ginkel RJ; Hoekstra HJ
Eur J Surg Oncol; 2005 Sep; 31(7):778-83. PubMed ID: 15993029
[TBL] [Abstract][Full Text] [Related]
15. In transit/local recurrences in melanoma patients after sentinel node biopsy and therapeutic lymph node dissection.
Rutkowski P; Nowecki ZI; Zurawski Z; Dziewirski W; Nasierowska-Guttmejer A; Switaj T; Ruka W
Eur J Cancer; 2006 Jan; 42(2):159-64. PubMed ID: 16324835
[TBL] [Abstract][Full Text] [Related]
16. Sentinel lymphonodectomy does not increase the risk of loco-regional cutaneous metastases of malignant melanomas.
Kretschmer L; Beckmann I; Thoms KM; Haenssle H; Bertsch HP; Neumann Ch
Eur J Cancer; 2005 Mar; 41(4):531-8. PubMed ID: 15737557
[TBL] [Abstract][Full Text] [Related]
17. Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma.
van Akkooi AC; Bouwhuis MG; van Geel AN; Hoedemaker R; Verhoef C; Grunhagen DJ; Schmitz PI; Eggermont AM; de Wilt JH
Eur J Surg Oncol; 2007 Feb; 33(1):102-8. PubMed ID: 17161577
[TBL] [Abstract][Full Text] [Related]
18. Sentinel-lymph-node biopsy (SLNB) for melanoma is not complication-free.
Wasserberg N; Tulchinsky H; Schachter J; Feinmesser M; Gutman H
Eur J Surg Oncol; 2004 Oct; 30(8):851-6. PubMed ID: 15336731
[TBL] [Abstract][Full Text] [Related]
19. Combined inguinal and pelvic lymph node dissection for stage III melanoma.
Hughes TM; Thomas JM
Br J Surg; 1999 Dec; 86(12):1493-8. PubMed ID: 10594495
[TBL] [Abstract][Full Text] [Related]
20. Factors predicting the risk of in-transit recurrence after sentinel lymphonodectomy in patients with cutaneous malignant melanoma.
Kretschmer L; Beckmann I; Thoms KM; Mitteldorf C; Bertsch HP; Neumann C
Ann Surg Oncol; 2006 Aug; 13(8):1105-12. PubMed ID: 16865591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
